Bernstein maintains Eli Lilly stock Outperform, $1,100 target
Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...
Hosted on MSN42m
Minnesota insulin lawsuit: 'Major development' in litigation
Minnesota Attorney General Keith Ellison is expected to announce a "major development" in the litigation against three large ...